Multimodal biomarker investigation on efficacy and mechanism of action for the mammalian target of rapamycin inhibitor, temsirolimus, in a preclinical mammary carcinoma oncomouse model: A translational medicine study in support for early clinical development

Journal of Pharmacology and Experimental Therapeutics

Volumn 339, Issue 2, 2011, Pages 421-429

  Wang, Xinkang ^a   Zhan, Yutian ^a   Zhao, Lei ^a   Alvarez, John ^a   Chaudhary, Inder ^a   Zhou, Bin Bing ^a   Abraham, Robert T ^a   Feuerstein, Giora Z ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCL 779; PHOSPHOPROTEIN; PHOSPHOPROTEIN S6; RAPAMYCIN; TEMSIROLIMUS; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CELL INFILTRATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RELEASE; DRUG TARGETING; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GROWTH;

ANIMALS; BIOMARKERS, PHARMACOLOGICAL; CELL LINE, TUMOR; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; INFUSIONS, INTRAVENOUS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TRANSLATIONAL MEDICAL RESEARCH; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80054791210     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.185249     Document Type: Article

References (38)

1. Abraham RT and Eng CH (2008) Mammalian target of rapamycin as a therapeutic target in oncology. Expert Opin Ther Targets 12:209-222. (Pubitemid 351284963)
2. Allavena P, Sica A, Garlanda C, and Mantovani A (2008) The Yin-Yang of tumorassociated macrophages in neoplastic progression and immune surveillance. Immunol Rev 222:155-161. (Pubitemid 351430369)
3. Amornphimoltham P, Patel V, Leelahavanichkul K, Abraham RT, and Gutkind JS (2008) A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancer. Cancer Res 68:1144-1153. (Pubitemid 351272233)
4. Boni JP, Leister C, Bender G, Fitzpatrick V, Twine N, Stover J, Dorner A, Immermann F, and Burczynski ME (2005) Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer. Clin Pharmacol Ther 77:76-89. (Pubitemid 40075391)
5. Brown EJ, Beal PA, Keith CT, Chen J, Shin TB, and Schreiber SL (1995) Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature 377:441-446.
6. Brown EJ and Schreiber SL (1996) A signaling pathway to translational control. Cell 86:517-520. (Pubitemid 26299483)
7. Chiang GG and Abraham RT (2007) Targeting the mTOR signaling network in cancer. Trends Mol Med 13:433-442. (Pubitemid 47570021)
8. Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G, and Milella M(2006) Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 66:5549-5554. (Pubitemid 43927103)
9. De Palma M and Lewis CE (2011) Cancer: macrophages limit chemotherapy. Nature 472:303-304.
10. Dormond O, Madsen JC, and Briscoe DM (2007) The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells. J Biol Chem 282:23679-23686. (Pubitemid 47311969)
11. Frost P, Moatamed F, Hoang B, Shi Y, Gera J, Yan H, Frost P, Gibbons J, and Lichtenstein A (2004) In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood 104:4181-4187. (Pubitemid 39620172)
12. Fung AS, Wu L, and Tannock IF (2009) Concurrent and sequential administration of chemotherapy and the mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts. Clin Cancer Res 15:5389-5395.
13. Furuya M and Yonemitsu Y (2008) Cancer neovascularization and proinflammatory microenvironments. Curr Cancer Drug Targets 8:253-265. (Pubitemid 351881351)
14. Geoerger B, Kerr K, Tang CB, Fung KM, Powell B, Sutton LN, Phillips PC, and Janss AJ (2001) Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 61:1527-1532. (Pubitemid 34292583)
15. Grote T, Siwak DR, Fritsche HA, Joy C, Mills GB, Simeone D, Whitcomb DC, and Logsdon CD (2008) Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: accurate detection of CA19-9 levels in pancreatic cancer. Proteomics 8:3051-3060.
16. Guertin DA and Sabatini DM (2009) The pharmacology of mTOR inhibition. Sci Signal 2:pe24.
17. Guy CT, Cardiff RD, and Muller WJ (1992) Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12:954-961.
18. Heng DY and Bukowski RM (2008) Anti-angiogenic targets in the treatment of advanced renal cell carcinoma. Curr Cancer Drug Targets 8:676-682.
19. Huang S, Bjornsti MA, and Houghton PJ (2003) Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther 2:222-232.
20. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
21. Le Tourneau C, Faivre S, Serova M, and Raymond E (2008) mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work? Br J Cancer 99:1197-1203.
22. Leek RD and Harris AL (2002) Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia 7:177-189. (Pubitemid 38420774)
23. Li WW, Hutnik M, and Gehr G (2008) Antiangiogenesis in haematological malignancies. Br J Haematol 143:622-631.
24. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, and Pollard JW (2003) Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 163:2113-2126. (Pubitemid 37310040)
25. Lin EY, Li JF, Bricard G, Wang W, Deng Y, Sellers R, Porcelli SA, and Pollard JW (2007) Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages. Mol Oncol 1:288-302. (Pubitemid 350181649)
26. Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, Qian H, Xue XN, and Pollard JW (2006) Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 66:11238-11246. (Pubitemid 46009952)
27. Liu M, Howes A, Lesperance J, Stallcup WB, Hauser CA, Kadoya K, Oshima RG, and Abraham RT (2005) Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer. Cancer Res 65:5325-5336. (Pubitemid 40827345)
28. Maglione JE, Moghanaki D, Young LJ, Manner CK, Ellies LG, Joseph SO, Nicholson B, Cardiff RD, and MacLeod CL (2001) Transgenic polyoma middle-T mice model premalignant mammary disease. Cancer Res 61:8298-8305. (Pubitemid 33091625)
29. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H, and Sawyers CL (2001) Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 98:10314-10319. (Pubitemid 32803017)
30. Podsypanina K, Lee RT, Politis C, Hennessy I, Crane A, Puc J, Neshat M, Wang H, Yang L, Gibbons J, et al. (2001) An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci U S A 98:10320-10325. (Pubitemid 32803018)
31. Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, Leister C, Korth- Bradley J, Hanauske A, and Armand JP (2004) Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22:2336-2347. (Pubitemid 41115390)
32. Sehgal SN, Molnar-Kimber K, Ocain TD, and Weichman BM (1994) Rapamycin: a novel immunosuppressive macrolide. Med Res Rev 14:1-22. (Pubitemid 24035973)
33. Shor B, Zhang WG, Toral-Barza L, Lucas J, Abraham RT, Gibbons JJ, and Yu K (2008) A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. Cancer Res 68:2934-2943. (Pubitemid 351556294)
34. Teachey DT, Obzut DA, Cooperman J, Fang J, Carroll M, Choi JK, Houghton PJ, Brown VI, and Grupp SA (2006) ThemTORinhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood 107:1149-1155. (Pubitemid 43156317)
35. Wan X, Shen N, Mendoza A, Khanna C, and Helman LJ (2006) CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1α/VEGF signaling. Neoplasia 8:394-401.
36. Wang X, Wang H, Xu L, Rozanski DJ, Sugawara T, Chan PH, Trzaskos JM, and Feuerstein GZ (2003) Significant neuroprotection against ischemic brain injury by inhibition of the MEK1 protein kinase in mice: exploration of potential mechanism associated with apoptosis. J Pharmacol Exp Ther 304:172-178.
37. Yu K, Toral-Barza L, Discafani C, Zhang WG, Skotnicki J, Frost P, and Gibbons JJ (2001) mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 8:249-258.
38. Zhao L, Zhan Y, Rutkowski JL, Feuerstein GZ, and Wang X (2010) Correlation between 2- and 3-dimensional assessment of tumor volume and vascular density by ultrasonography in a transgenic mouse model of mammary carcinoma. J Ultrasound Med 29:587-595.